Targeted therapy and radiotherapyfor brain metastases in non-small lung cancer patients: When is the

• 作 者: Dongmei Chen XiangyingMeng Shikai Wu Yang Cong Bing Sun Chao Liu Ge Shen Hongjun Gao Xiaoqing Liu
• 机 构: Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beiji
• 出 处: 2016年北京市肿瘤放疗年会
• 发表日期: 2016年5期
• 关键词: Targeted therapy Radiotherapy Brain metastasis Non-small cell lung cancer Concur

　　The clinical outcomes of the sequential versus concurrenttherapy of targeted therapy andradiotherapy are still unconfirmedin patients with brain metastases (BM).To evaluate the role ofthe combination therapy, a total of 208 advanced non-small cell lung cancer (NSCLC) patients were reviewed.Thirty-seven patients underwent targeted therapy only, seventy-nine patients received radiotherapy only, and ninety-two patientsperformedcombination therapy.Patients with combination therapy were stratified by prior targeted therapy, prior radiotherapyand concurrent therapy.Kaplan-Meier and Cox regression methods were performed to evaluate overall survival after brain metastasis (BMOS).At a median follow-up of 30.8 months, the combination therapy showed a longer survival with median BMOS of 18.7 months, comparing the targeted therapy alone and radiotherapy alone, 15.1 months and 9.7 months respectively (p=0.011).In combination group, there was significant difference in the BMOS of patients with concurrent therapy, versus sequential therapy (the median BMOS of concurrent therapy was not reached, p=0.042).The combination therapy showed a favorite survival andprovided an option for NSCLC patients with BM.Concurrent therapy for BM are more promising effective treatments in NSCLC patients, versus prior targeted therapy or prior radiotherapy.Further prospective randomized trials with large population are required toconfirm these results.